ClinicalTrials.gg
RecruitingNCT05801471Updated Jan 2, 2026

Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression

An observational study in Glaucoma, sponsored by Centervue SpA. Recruiting at 2 sites in Italy. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Centervue SpA · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.

Planned enrollment
5th of 13
200 · median 200
Started
2022
the only one that year
Observational
13 of 53
6 open now
Registered
40th of 53
by date

Among the 53 studies in Glaucoma with a site in Italy, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2022, is one of 13 observational ones, and was the 40th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Glaucoma with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult, both males and females, 40-90 years old with diagnosis of Glaucoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glaucomatous optic nerve head in both eyes;
  • Age between 40 and 90 years;
  • Best Corrected Visual Acuity ≤ 0.3 [logMar];
  • Spherical refraction between -6D and +6D;
  • Astigmatism between -2D and +2D.

Exclusion criteria

Exclusion Criteria:

  • Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment;
  • Any ocular pathology that can affect visual field other than glaucoma;
  • Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss;
  • Inability to obtain reliable perimetric examinations;
  • Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).

    Equivalence will be defined as the 95% confidence Intervals of the mean difference between the slopes estimated with the two devices being within ± 0.1 dB/year

    Time frame: 1 visit every 4 months (10 visits total), up to 3 years

Secondary outcomes

  1. Difference in time to identify progression between Compass and HFA using an event analysis

    Time of first detectable change \[years\]

    Time frame: 1 visit every 4 months (10 visits total), up to 3 years

  2. Quantification of the effect of the integration of the rate of progression of structural metrics into the calculation of the rate of progression of the MD

    Quantification of the effect of the integration of the rate of progression of structural metrics (mainly the retinal nerve fiber layer thickness, microns/year) into the calculation of the rate of progression of the MD. This effect will be quantified as the improvement in the equivalence metric defined for Outcome 1 The integration of structural OCT RNFL thickness information into progression analysis will be done using a Bayesian Linear Regression approach as suggested by Russel at al.\[\*\] \[\*\] R.A. Russel at al.; "Improved Estimates of Visual Field Progression Using Bayesian Linear Regression to Integrate Structural Information in Patients with Ocular Hypertension"; IOVS May 2012; 53(6): 2760-2769.

    Time frame: 1 visit every 4 months (10 visits total), up to 3 years

07

Study locations

2 of 2 sites recruiting
  • Clinica oculistica Ospedale San Paolo
    Milan, Milano 20142, Italy
    Recruiting
    • Luca M Rossetti, Prof. · Contactluca.rossetti@unimi.it · 02/81844556
    • Luca M. Rossetti, Prof. · Principal investigator
    • Paolo Fogagnolo, Dott. · Sub investigator
  • Glaucoma Research Center, IRCCS Fondazione "G.B. Bietti"
    Roma, Roma 00184, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Nov 2028, 78 months after the start.

Of 135 observational studies under Glaucoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 208. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Apr 6, 2023
StartActual
May 6, 2022
Primary completionEst.
Nov 6, 2028
CompletionEst.
Nov 6, 2028
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05801471
Lead sponsor
Centervue SpA
Responsible party
Sponsor
First posted
Apr 6, 2023
Start date
May 6, 2022
Primary completion
Nov 6, 2028 (estimated)
Completion
Nov 6, 2028 (estimated)
Last update
Jan 2, 2026

Study contacts

Chiara Rui
Contact
chiara.rui@icare-world.com
+39 049 501 8399
Luca M. Rossetti, Prof.
principal investigator · Clinica oculistica Ospedale San Paolo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion